| 张扬,刘双江,邹晓译,谭强.通心络胶囊联合阿托伐他汀治疗经皮冠状动脉介入术后支架内再狭窄患者的疗效及对其炎性因子的影响[J].中国临床保健杂志,2018,21(4):490-493. |
| 通心络胶囊联合阿托伐他汀治疗经皮冠状动脉介入术后支架内再狭窄患者的疗效及对其炎性因子的影响 |
| The effect of Tongxinluo capsule combined with atto vastatin on patients with stent restenosis after percutaneous coronary intervention and its effect on inflammatory factors |
| 投稿时间：2018-03-17 |
| DOI：10.3969/J.issn.1672-6790.2018.04.014 |
| 中文关键词: 冠状动脉再狭窄 血管成形术,气囊,冠状动脉 C反应蛋白质 白细胞介素6 肿瘤坏死因子α |
| 英文关键词: Coronary restenosis Angioplasty,balloon,coronary C-reactive protein Interleukin-6 Tumor necrosis factor-alpha 〖FL |
| 基金项目: |
|
| 摘要点击次数: 6254 |
| 全文下载次数: 4404 |
| 中文摘要: |
| 目的 探讨运用通心络胶囊以及阿托伐他汀治疗经皮冠状动脉介入治疗手术(PCI)后支架内再狭窄患者的疗效以及对患者炎性因子水平的影响。方法 选取接受经皮冠状动脉介入治疗后并发支架内再狭窄患者120例作为研究对象,使用随机数字表法对其进行分组,分成观察组60例和对照组60例。对照组使用阿托伐他汀进行治疗,观察组则使用阿托伐他汀联合通心络胶囊进行治疗,分析患者治疗前后组内及组间的效果差异。结果 在完成为期半年的治疗之后,观察组的再狭窄程度[(24.87±4.76)%]显著低于对照组[(30.21±3.43)%],P<0.05；再狭窄率(3.33%)显著对照组(13.33%),差异有统计学意义(χ2=3.927,P<0.05)。观察组患者的超敏C反应蛋白(hs-CRP)[(2.52±0.31)mg/L]、白细胞介素6(IL-6)[(6.81±4.02)ng/L]、肿瘤坏死因子α(TNF-α)[(25.39±9.88)ng/L]等均显著低于治疗前患者的炎性因子水平[(5.61±0.52)mg/L、(14.19±4.64)ng/L、(63.47±18.11)ng/L],差异均有统计学意义(t=39.536、9.311、14.298,均P<0.05)。对照组hs-CRP[(3.51±0.79)mg/L]、IL-6[(8.76±3.33)ng/L]、TNF-α[(34.96±11.87)ng/L]等炎性因子水平显著低于治疗前患者的hs-CRP[(5.78±0.93)mg/L]、IL-6[(13.05±4.85)ng/L]、TNF-α[(62.08±17.95)ng/L]等,差异有统计学意义(t=14.410、5.648、9.762,均P<0.05)。同时治疗后阶段观察组各项指标均低于对照组(t=9.036、2.894、4.800,均P<0.05)。结论 经皮冠状介入手术治疗后患者运用通心络胶囊联合阿托伐他汀可有效降低其支架内再狭窄的发生率,预防不良心血管事件地发生,并且有利于降低血清炎性因子水平。 |
| 英文摘要: |
| Objective To investigate the effect of Tongxinluo capsule and atorvastatin on patients with stent restenosis after percutaneous coronary intervention (PCI) and the influence on inflammatory factors.Methods 120 patients with stent restenosis patients treated by percutaneous coronary intervention were divided into the observation group of 60 cases and 60 cases in the control group.The control group used atorvastatin treatment,observation group used atorvastatin combined with Tongxinluo capsule treatment.Results After six months of treatment,the restenosis in the observation group(24.87±4.76)% was significantly lower than that in the control group[(30.21±3.43)%],P<0.05；the restenosis rate (3.33 %) was significantly higher than that of the control group (13.33%)(χ2=3.927,P<0.05).The hypersensitive C reaction protein(hs-CRP)[(2.52±0.31)mg/L],interleukin 6(IL-6)[(6.81±4.02)ng/L],tumor necrosis factor α(TNF-α)[(25.39±9.88)ng/L] in the observation groupSignificantly lower than the level of hs-CRP[(5.61±0.52)mg/L],IL-6[(14.19±4.64)ng/L],TNF-α[(63.47±18.11)ng/L] before treatment,all the differences are statistically significant(t=39.536,9.311,4.298,P<0.05).The level of hs-CRP[(3.51±0.79)mg/L],IL-6[(8.76±3.33)ng/L],TNF-α[(34.96±11.87)ng/L]of control group was significantly lower than the level of hs-CRP[(5.78±0.93)mg/L],IL-6[(13.05±4.85)ng/L],TNF-α[(62.08±17.95)ng/L],that of patients before treatment,all the differences are statistically significant(t=14.410,5.648,9.762.P<0.05).At the same time,all the indexes of the observation group were lower than the control group after the treatment(t=9.036,2.894,4.800.P<0.05).Conclusion Tongxinluo capsule combined with Atto vastatin can effectively reduce the incidence of restenosis in stent and prevent adverse cardiovascular events for patients with percutaneous coronary intervention.And it is beneficial to reduce the level of serum inflammatory factors. |
|
查看全文
|
| 关闭 |
|
|
|